The endovascular surgery in China has been developing from none to a few, from a few to many, from primary to refinement, from blind to directional, and it is expecting to grow even rapidly as "spring bamboo after a timely rain" in which "science is the first motive force" and a consistent diligence and endeavor putting into it from vascular scientists and practitioners has been playing a distinctively important role. It has experienced a hard initiation and developing process. Describing here is mainly the development of endoluminal vascular surgery for major vein and artery, i. e., the vena cava and the aorta, however it was still from research and practice of the medium-sized vessels. Until now, we have treated more than 137 cases. The total number of patients with aortic dissection treated by endografting should be more than 1000. The endoluminal treatment, including the hybrid or semi-interventional method for treating aortic dissection is very likely to have a particularly better future in comparison to the treatment for those with the infra-renal abdominal aortic aneurysm in which requires, unlikely the surgery for handling aortic dissections with long segmental involvement of the aorta, less surgical demanding. It is predicted that the distinctively difference we have had now between China and the Western World in term of the incidence of abdominal aortic aneurysm and aortic dissections and their related treatment would be gradually disappeared in the future. The endoluminal treatment for treating greater vessel disorders has less mortality and postoperative complications, such as hyperplagia, stoke or cerebral deficits, paralysis, etc., less rehabilitation is required and thus has a fruitful future.